MK-677 (Ibutamoren): Growth Hormone, Appetite and Side Effects

  • By Steroid Warehouse
  • November 13, 2026
  • Reading Time: 10 mins
MK-677 (Ibutamoren): Growth Hormone, Appetite and Side Effects

MK-677, also called ibutamoren, is an oral compound that mimics ghrelin, the hormone that tells the brain to release growth hormone and to eat. It is not a steroid and not a SARM, and it has never been approved as a medicine.

It is popular because it is swallowed rather than injected and because it raises growth hormone and IGF-1 measurable on blood work. This guide covers what the receptor does, what trials measured, what goes wrong, and which numbers are worth tracking.

Key facts about MK-677

Chemical nameIbutamoren, also written MK-677
ClassOral growth hormone secretagogue, ghrelin receptor agonist
Molecular formulaC27H36N4O5S, molecular weight 528.7
RouteOral, usually as capsules or liquid
Approved statusNot approved as a medicine anywhere
Main measurable effectRise in growth hormone and IGF-1, plus appetite
Main practical concernsAppetite, water retention, glucose, and no long term safety data
MK-677 in numbers
528.7
Molecular weight, C27H36N4O5S
0
Countries where it is approved
10-25 mg
Common practice, no approved dose

IGF-1 is the readout that moves first. Body composition moves later, less and with more individual variation.

What MK-677 is

Ibutamoren belongs to a class called growth hormone secretagogues. These compounds were developed in the 1990s, before ghrelin itself was discovered, by looking for small molecules that would make the pituitary release growth hormone. When ghrelin was identified as the natural ligand for the same receptor, the class got its explanation: these drugs imitate a hunger signal.

Three distinctions are worth keeping straight, because forum posts blur them constantly:

  • Not a steroid. It does not bind the androgen receptor and does not build muscle through that route.
  • Not a SARM. It is not selective for androgen tissue and has nothing to do with that family of drugs.
  • Not growth hormone. It does not add hormone from outside. It asks your pituitary to release more of its own, in pulses.

How it raises growth hormone

MK-677 binds the growth hormone secretagogue receptor, the same receptor ghrelin uses, in the pituitary and the hypothalamus. Activation increases the size of growth hormone pulses rather than producing a constant level, which is the physiological difference between this class and injected growth hormone.

A 2023 review of growth hormone secretagogues describes the feedback that limits the effect: IGF-1 rises in response to growth hormone, and IGF-1 itself feeds back to restrain further release. That is why these compounds are described as restoring a rhythm rather than pushing a constant flood. In older adults the review reports that growth hormone output can be restored toward levels seen in people in their twenties, with an increase in fat free mass and a redistribution of fat toward the limbs.

What this mechanism does not promise. A restored growth hormone rhythm in a 65 year old is not the same as supraphysiological growth hormone in a 25 year old bodybuilder. The trials were run in older and clinical populations, not in trained young men chasing size.
The loop MK-677 plugs into
1
Ghrelin signal
The body releases ghrelin, which binds the growth hormone secretagogue receptor in the brain and pituitary.
2
Bigger GH pulses
The pituitary releases growth hormone in larger pulses, mostly at night. MK-677 imitates the ghrelin signal rather than adding hormone.
3
IGF-1 rises and brakes
Growth hormone raises IGF-1, and IGF-1 feeds back to limit further release. This ceiling is why more is not linearly better.

The same receptor explains the appetite: ghrelin is the hunger signal, so hunger is the mechanism working, not a side effect.

What the trials measured

Most of the clinical research on ibutamoren comes from small studies in older adults and in specific conditions, not from performance research. What the literature supports:

EndpointWhat was reportedHow strong the evidence is
Growth hormone and IGF-1Clear, dose related increases in bothConsistent across studies, this is the reliable part
Fat free massIncrease reported in older adultsSmall studies, short duration
Fat distributionShift of fat toward the limbs described in the reviewSmall studies, modest effect
Strength and performanceNot establishedNo reliable data in trained populations
AppetiteIncrease, consistent with the ghrelin mechanismReported by users and consistent with pharmacology

The honest summary: this compound does what it says on the hormone panel, and the body composition changes are smaller and less certain than the marketing suggests.

Appetite, weight and water

Because the target receptor is the ghrelin receptor, hunger is not a side effect in the accidental sense. It is part of the drug's action. A 2025 review of ghrelin biology describes the receptor as a regulator that goes well beyond hunger, involved in reward, glucose handling and whole body energy balance, which is also why the effects of stimulating it are broader than appetite alone.

In practice people report two things in the first weeks: eating more, and looking fuller. The second is partly water. Stimulating growth hormone and increasing food intake both tend to increase extracellular fluid, which is why ankles, hands and the face can look puffy. It usually settles, and it is not muscle.

What is not known

QuestionState of the evidence
Long term safety beyond a yearNot established, no large trials
Effect on glucose and insulin sensitivity with prolonged useUnclear, and this is the main theoretical concern with growth hormone elevation
Effect on pituitary function after stoppingPoorly described
Interaction with other compoundsAlmost no data
Quality of products sold onlineVariable, and unapproved status means no pharmacist check

Growth hormone and glucose are linked: growth hormone opposes insulin. Anyone raising growth hormone for months should be watching fasting glucose and HbA1c rather than assuming it is harmless because it is not a steroid.

A case worth reading

A 2024 case report describes a 40 year old man who developed bilateral gynecomastia and hypogonadotropic hypogonadism after six months of taking commercially sold performance supplements for the gym. Analysis found the products contained RAD-140, MK-677 and cardarine, along with undeclared testosterone, estradiol and growth hormone.

The point of the case is not that MK-677 caused gynecomastia on its own. The point is that the man did not know what he was taking, and neither would anyone reading a label that did not list those compounds. Whatever compound you choose, knowing exactly what is in the product is the first safety measure, and it comes before dose, timing and everything else.

Dose, forms and what people actually run

There is no approved dose, so what follows describes common practice, not a recommendation. It is usually sold next to SARMs rather than steroids, so the SARM category is where to compare what is available.

ItemCommon practiceReality check
FormCapsules or liquid, taken by mouthLiquid products make accurate dosing harder than capsules
Daily amountUsually 10 to 25 mgNo validated male dose exists, and effects on IGF-1 are dose related
TimingEvening, before sleepGrowth hormone is released mostly during sleep, but timing has not been compared in trials
Duration8 to 12 weeks, sometimes longerNo long term safety data beyond that window
Cycle supportOften stacked with SARMsStacking multiplies unknowns, not just effects

Two practical points follow from the pharmacology. First, because the effect is mediated by your own pituitary, a bigger dose does not produce a proportional result once IGF-1 feedback kicks in. Second, because appetite rises, the dose has a direct effect on how much you eat, which changes body composition independently of growth hormone.

MK-677 compared with injected growth hormone

These are different tools and they are marketed as if they were the same thing.

MK-677Injected growth hormone
How it worksStimulates your own pulses through the ghrelin receptorAdds exogenous hormone directly
RouteOralSubcutaneous injection
ControlLimited by IGF-1 feedbackDose determines the level, with no feedback ceiling
MonitoringIGF-1, glucoseIGF-1, glucose, and medical supervision in approved use
Approved statusNot approvedApproved for specific indications under a doctor

Growth hormone itself is a prescription medicine with defined indications, and its misuse carries well described risks including fluid retention, joint pain, carpal tunnel symptoms and effects on glucose. A secretagogue is not a safer version of the same thing: it is a different mechanism with its own unknowns.

Blood work and monitoring

MarkerWhy it mattersWhen
IGF-1The most direct readout of growth hormone activityBaseline, week 4, then every 8 to 12 weeks
Fasting glucose and HbA1cGrowth hormone opposes insulinBaseline and every 3 months
Blood pressure and weightWater retention shows up here firstWeekly
Total and free testosterone, LH, FSHTo see whether the axis is affected, especially with stacked productsBaseline and after 8 weeks
ProlactinRelevant if libido or breast symptoms appearIf symptoms appear

Example structure, not a recommendation

The table below is a common shape for a run of this kind, written out so the timing and the checkpoints are visible. It is not advice, not a protocol to copy, and not a substitute for a doctor who has seen your blood work.

StageWhat people typically doWhat to check
Week 110 mg in the eveningBaseline IGF-1, fasting glucose
Weeks 2 to 810 to 25 mg, depending on toleranceWatch appetite, sleep, ankle swelling
Week 8IGF-1 and glucose recheckDecide on continuation from numbers
AfterStop and reassess in 4 weeksIGF-1 returns toward baseline
Read this as an outline, not a prescription
Doses vary by body weight, experience and medical history. The only parts worth copying are the checkpoints: baseline, midpoint, end, and a review of the axis afterwards.

Frequently Asked Questions

Is MK-677 a steroid or a SARM? +
Neither. It is an oral growth hormone secretagogue that acts on the ghrelin receptor. It does not bind the androgen receptor.
Does MK-677 really raise IGF-1? +
Yes. Growth hormone and IGF-1 rise in a dose related way, and that part of the literature is consistent. Body composition changes are smaller and less certain than the hormone changes.
Why does MK-677 make you hungry? +
It activates the ghrelin receptor, and ghrelin is the hunger signal. Appetite increase is part of the mechanism, not a random side effect.
Does MK-677 affect blood sugar? +
Growth hormone opposes insulin, so fasting glucose and HbA1c are the markers to watch. Long term data on glucose with prolonged use is limited, which is itself a reason to monitor.
Is the puffiness from MK-677 water or muscle? +
Mostly water, especially in the first weeks. Growth hormone elevation and higher food intake both increase fluid retention. It is not lean tissue.
Is MK-677 approved anywhere? +
No. It was developed as a drug candidate and never reached approval. Everything sold is unapproved, which is why the supplier and the batch code matter more than the label artwork.

Where this fits on this site

Ibutamoren is usually sold next to SARMs rather than steroids, and our SARM category is where to compare what is available. For the recovery side of any cycle, start with post cycle therapy. If you are weighing growth hormone pathways against androgen pathways, the Anavar guide shows the androgen route, and the Ostarine article covers the receptor that MK-677 is often confused with.

Medical disclaimer. This article is informational and does not replace advice from a licensed physician. Ibutamoren is unapproved, long term safety data is thin, and raising growth hormone has measurable effects on glucose and fluid balance.